Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab Journal Article
| Authors: | Hellmann, M. D.; Chaft, J. E.; Rusch, V.; Ginsberg, M. S.; Finley, D. J.; Kris, M. G.; Price, K. A. R.; Azzoli, C. G.; Fury, M. G.; Riely, G. J.; Krug, L. M.; Downey, R. J.; Bains, M. S.; Sima, C. S.; Rizk, N.; Travis, W. D.; Rizvi, N. A.; Paik, P. K. |
| Article Title: | Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab |
| Abstract: | Purpose: Bevacizumab improves survival in lung adenocarcinomas. The potential anti-tumor benefit of bevacizumab in squamous cell lung cancers (SQCLCs) is unknown because bevacizumab is contraindicated in patients with advanced SQCLC due to an increased risk of hemoptysis. The risk of hemoptysis may be eliminated in patients with resected SQCLCs. We evaluated the safety of adjuvant bevacizumab in patients with resected SQCLCs and other lung cancers at high risk of hemoptysis. Methods: As part of a prospective, phase II trial, patients with lung cancers at high risk of hemoptysis (defined by SQCLC histology, tumor near the central blood vessels, or history of hemoptysis) were treated with adjuvant bevacizumab following neo-adjuvant chemotherapy and complete surgical resection. Bevacizumab 15 mg/kg was given once every 3 weeks for up to 1 year. Patients were followed for safety and survival. Results: Thirteen patients with high-risk features were treated: 7 patients had SQCLC, 3 had central tumors, and 3 had previous hemoptysis. No hemoptysis of any grade was seen following treatment with bevacizumab. Five of 13 patients experienced grade 1 bleeding (epistaxis, gum bleeding). Hypertension and lymphopenia were seen. Conclusions: In a cohort of patients with resected lung cancers at high risk of hemoptysis, including those with SQCLC, treatment with adjuvant bevacizumab did not result in hemoptysis of any grade. © 2013 Springer-Verlag Berlin Heidelberg. |
| Keywords: | adult; cancer survival; clinical article; controlled study; treatment outcome; aged; disease-free survival; middle aged; cancer surgery; clinical trial; fatigue; histopathology; carcinoma, squamous cell; bevacizumab; cisplatin; advanced cancer; drug safety; hypertension; adjuvant therapy; postoperative care; combined modality therapy; nuclear magnetic resonance imaging; positron emission tomography; prospective study; adenocarcinoma; edema; computer assisted tomography; multiple cycle treatment; phase 2 clinical trial; cohort studies; neoplasm recurrence, local; anemia; bleeding; lung non small cell cancer; nausea; lung neoplasms; cohort analysis; deep vein thrombosis; antineoplastic activity; high risk patient; docetaxel; hyperglycemia; lymphocytopenia; pneumonia; rash; hyponatremia; karnofsky performance status; adjuvant chemotherapy; acute heart infarction; pleura effusion; hyperbilirubinemia; lung squamous cell carcinoma; endpoint determination; treatment contraindication; angiogenesis inhibitors; lung function test; epistaxis; drug dose sequence; cerebrovascular accident; clinical examination; hypernatremia; hemoptysis; kidney dysfunction; hypertransaminasemia; gingiva bleeding; antibodies, monoclonal, humanized; non-small cell lung cancers; faintness; squamous cell lung cancers |
| Journal Title: | Cancer Chemotherapy and Pharmacology |
| Volume: | 72 |
| Issue: | 2 |
| ISSN: | 0344-5704 |
| Publisher: | Springer |
| Date Published: | 2013-08-01 |
| Start Page: | 453 |
| End Page: | 461 |
| Language: | English |
| DOI: | 10.1007/s00280-013-2219-5 |
| PROVIDER: | scopus |
| PUBMED: | 23811982 |
| PMCID: | PMC4653739 |
| DOI/URL: | |
| Notes: | - "Export Date: 4 September 2013" - "CODEN: CCPHD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work